This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Knol, J. A. Articles by Lawrence, T. S. Search for Related Content PubMed PubMed Citation Articles by Knol, J. A. Articles by Lawrence, T. S.

Incorporation of 5-Bromo-2'-deoxyuridine into Colorectal Liver Metastases and Liver in Patients Receiving a 7-Day Hepatic Arterial Infusion¹

Departments of Surgery [J. A. K.], Internal Medicine [W. D. E., S. C. W.], Radiation Oncology [T. S. L., J. M. R.], and Pharmacology [P. L. S., S. D., Z. Y., W. D. E.], University of Michigan Medical School, Ann Arbor, Michigan 48109

Preclinical and clinical data suggest that the combination of hepatic arterial bromodeoxyuridine (BrdUrd), a thymidine analogue radiation sensitizer, and high-dose three-dimensional conformal radiation therapy offer a high potential for improving the local control of intrahepatic cancers. A key step in the design of a successful protocol is to determine in patients the conditions for BrdUrd administration that would be expected to produce selective radiosensitization of the tumor. Therefore, we designed a clinical trial to assess BrdUrd incorporation into the DNA of hepatic colorectal metastases and normal liver after a 7-day continuous BrdUrd infusion at a dose rate of 25 mg/kg/day (the maximal tolerated dose for a 14-day infusion) for patients undergoing laparotomy for either resection of liver metastases or hepatic arterial catheter and pump placement. Thirteen patients were entered into this study. We found that the average replacement of thymidine by BrdUrd in the tumor and normal liver were 11.6 ± 1.2% and 1.1 ± 0.2%, respectively. This extent of incorporation would be expected to produce a single fraction radiation enhancement of 1.5 in the tumor without detectable sensitization of the normal liver. Immunohistochemical staining for BrdUrd revealed heterogeneity of incorporation with a range of approximately 60–80% of the cells labeled in different regions of the specimens. These findings suggest that hepatic arterial BrdUrd given at this dose and schedule has a high likelihood of producing clinically significant radiosensitization for patients with hepatic metastases from colorectal cancer. Furthermore, the demonstrated selectivity of tumor perfusion that can be obtained with hepatic arterial infusion combined with the high proliferative rate of colorectal metastases (versus normal liver) suggests that these patients may be good candidates for tumor-directed gene transfer therapy by using regionally delivered retroviral vectors.

¹ These investigations were supported in part by NIH Grants MO1 RR 00042, PO1 CA 42761, and an American Society of Clinical Oncology Clinical Research Career Development Award (J. M. R.).

² To whom requests for reprints should be addressed, at Department of Surgery, University of Michigan, 1500 Medical Center Drive, Ann Arbor, MI 48109-0331.

Received 7/ 5/95. Accepted 7/21/95.

This article has been cited by other articles:

				S. E. Berry, T. W. Davis, J. E. Schupp, H.-S. Hwang, Niels de Wind, and T. J. Kinsella Selective Radiosensitization of Drug-resistant MutS Homologue-2 (MSH2) Mismatch Repair-deficient Cells by Halogenated Thymidine (dThd) Analogues: Msh2 Mediates dThd Analogue DNA Levels and the Differential Cytotoxicity and Cell Cycle Effects of the dThd Analogues and 6-Thioguanine Cancer Res., October 1, 2000; 60(20): 5773 - 5780. [Abstract] [Full Text]

				T. J. Kinsella, J. E. Schupp, T. W. Davis, S. E. Berry, H.-S. Hwang, K. Warren, F. Balis, J. Barnett, and H. Sands Preclinical Study of the Systemic Toxicity and Pharmacokinetics of 5-Iodo-2-deoxypyrimidinone-2'-deoxyribose as a Radiosensitizing Prodrug in Two, Non-Rodent Animal Species: Implications for Phase I Study Design Clin. Cancer Res., September 1, 2000; 6(9): 3670 - 3679. [Abstract] [Full Text]

				T. J. Kinsella, K. A. Vielhuber, K. A. Kunugi, J. Schupp, T. W. Davis, and H. Sands Preclinical Toxicity and Efficacy Study of a 14-day Schedule of Oral 5-Iodo-2-pyrimidinone-2'-deoxyribose as a Prodrug for 5-Iodo-2'-deoxyuridine Radiosensitization in U251 Human Glioblastoma Xenografts Clin. Cancer Res., April 1, 2000; 6(4): 1468 - 1475. [Abstract] [Full Text]

				S. E. Berry, C. Garces, H.-S. Hwang, K. Kunugi, M. Meyers, T. W. Davis, D. A. Boothman, and T. J. Kinsella The Mismatch Repair Protein, hMLH1, Mediates 5-Substituted Halogenated Thymidine Analogue Cytotoxicity, DNA Incorporation, and Radiosensitization in Human Colon Cancer Cells Cancer Res., April 1, 1999; 59(8): 1840 - 1845. [Abstract] [Full Text] [PDF]